Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

The evolving treatment landscape in immune thrombocytopenia

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival